Ginlix AI
50% OFF

Analysis of Pien Tze Huang's Overseas Business Status and Challenges in Traditional Chinese Medicine Internationalization

#traditional_chinese_medicine #overseas_business #fda_certification #internationalization #片仔癀 #pharmaceutical_industry #market_challenges
A-Share
December 29, 2025

Unlock More Features

Login to access AI-powered analysis, deep research reports and more advanced features

About us: Ginlix AI is the AI Investment Copilot powered by real data, bridging advanced AI with professional financial databases to provide verifiable, truth-based answers. Please use the chat box below to ask any financial question.

Related Stocks

600436
--
600436
--

Based on the collected data and market information, I will provide a detailed analysis of Pien Tze Huang’s overseas business status and the challenges faced by Traditional Chinese Medicine (TCM) internationalization.


Analysis of Pien Tze Huang’s (600436.SS) Overseas Business Status
1. Core Financial Data

According to the latest market data, Pien Tze Huang’s current market capitalization is

102.68 billion RMB
, share price is 170.20 yuan, and price-to-earnings ratio is 42.44 times. The company’s performance has been under significant pressure in recent years:

Indicator Value Market Performance
Year-to-Date (YTD) -18.59% Significant Decline
1-Year Return -21.94% Sustained Weakness
3-Year Return -41.12% Long-Term Correction
Net Profit Margin 24.74% Still Strong Profitability
ROE 16.51% Good Shareholder Return

Key Issue: Overseas Revenue Accounts for Only 3.93%
, reflecting that the company’s internationalization process is seriously lagging behind.


2. Core Reasons Why TCM Internationalization Strategy Is Hard to Break Through
1. Regulatory Certification Barriers — The Most Critical Institutional Obstacle

FDA Certification Dilemma
is the primary obstacle to TCM internationalization:

  • Current Status
    : To date, no TCM has passed the U.S. FDA approval as a
    drug
  • Result
    : Most TCM products can only enter the U.S. market as
    dietary supplements
  • Impact
    : Failure to obtain drug status means inability to enter the mainstream medical system, limiting both brand premium and market share

According to academic research, the core regulatory challenges faced by TCM include:

Challenge Type Specific Performance
Technical Standard Differences Western medicine emphasizes single active ingredients, while TCM mostly uses compound preparations
Clinical Trial Requirements FDA requires strict double-blind randomized controlled trials, which are difficult for TCM to meet
Approval Process TCM lacks complete chemical composition and mechanism of action data
2. Cultural Cognition Differences — Deep-Seated Conceptual Obstacles

The

cultural gap
faced by TCM internationalization is reflected in multiple levels:

  • Cognitive Model Differences
    : Western medicine emphasizes “evidence-based medicine”, while TCM focuses on “holistic concept” and “syndrome differentiation and treatment”
  • Different Philosophical Foundations
    : TCM’s “Yin-Yang and Five Elements” theory is difficult to explain in modern scientific language
  • Efficacy Cognition
    : Western patients tend to prefer fast-acting drugs, while TCM emphasizes “treating both the symptoms and the root cause”
3. Market Trust Crisis
  • Quality Control Issues
    : Complex sources of Chinese medicinal materials, and safety hazards such as pesticide residues and heavy metals affect international reputation
  • Low Standardization
    : Lack of unified international quality standards
  • Impact of Negative Events
    : Safety issues of some TCM products in history have been amplified by international media
4. Decline of Traditional Channels and Challenges of Emerging Channels

According to the latest 2024 data:

Category Export Volume YoY Growth Rate Characteristics
Chinese Patent Medicine 400 million USD +10.6% Slow Growth
Health Products 660 million USD +20.9% Fast Growth
Chinese Medicinal Materials and Decoction Pieces Significant Decline -45.6% (Vietnam Market) Traditional Channel Decline

Structural Contradictions
:

  • The global TCM market size is expected to exceed 200 billion USD
  • However, Chinese patent medicine accounts for only 8% of TCM exports
  • Most exports are still raw materials and primary processed products

3. Specific Challenges of Pien Tze Huang’s Internationalization Strategy
1. Product Feature Limitations

As a

precious Chinese patent medicine
, Pien Tze Huang faces special challenges:

  • Core Ingredient Confidentiality
    : The formula contains precious ingredients such as natural musk, facing restrictions from international wildlife protection laws
  • Product Form
    : The traditional pill form does not conform to Western patients’ medication habits
  • Price Positioning
    : High-end positioning limits penetration into the mass market
2. Competitive Landscape
Market Main Competitors Pien Tze Huang’s Disadvantages
Southeast Asia Japanese Kampo, Korean Ginseng Insufficient Brand Awareness
Europe & America German Herbal Medicine, U.S. Dietary Supplements Lagging Channel Construction
Domestic Tong Ren Tang, Yunnan Baiyao Insufficient Overseas Layout Investment

4. Breakthrough Paths and Recommendations
Short-Term Strategies
  1. Leverage Cross-Border E-Commerce
    :

    • Platforms like TikTok Shop in Southeast Asia are growing rapidly
    • TCM-related health products have become one of the fastest-growing categories
    • Can expand through channels like Alibaba International Station
  2. Focus on Niche Markets
    :

    • Focus on overseas Chinese communities
    • Target Southeast Asian markets with some awareness of TCM culture
Medium-to-Long-Term Strategies
  1. Promote International Certification
    :

    • Strive to pass the FDA’s “Herbal Drug” channel certification
    • Establish clinical trial data that meets international standards
  2. Improve Product Standardization
    :

    • Establish a traceable quality control system
    • Obtain international certifications such as ISO
  3. Prioritize Cultural Communication
    :

    • Cultivate the market through TCM cultural experience centers and educational programs
    • Collaborate with international research institutions to conduct basic research

5. Conclusion

The problem that Pien Tze Huang’s overseas revenue accounts for only 3.93% is essentially a microcosm of the

systemic predicament of TCM internationalization
. This predicament is caused by multiple factors such as regulatory barriers, cultural differences, quality standards, and channel construction.

From an industrial perspective, TCM internationalization is not just a commercial issue, but a comprehensive challenge involving

cultural export, standard setting, and discourse power competition
. To achieve a breakthrough, it requires collaborative efforts from enterprises, governments, and industry organizations, with continuous investment in product research and development, quality improvement, cultural communication, and international cooperation.

For Pien Tze Huang, while maintaining its domestic market advantage, it needs to formulate a more proactive internationalization strategy and gradually increase its overseas revenue share to achieve more balanced and sustainable development.


References

[1] Research on the Path of Cross-Border E-Commerce in the Internationalization of TCM Health Care Products (https://pdf.hanspub.org/ecl_2316614.pdf)
[2] TCM Faces Great Challenges: Revealing the Truth Behind the Failure to Obtain FDA Certification (https://www.wenxiaobai.com/api/expends/detail?article=004bfaf9-a484-4248-9726-8acf3f16c95a)
[3] Current Situation and Internationalization of TCM from the Perspective of Chinese Culture and System (https://etd.ohiolink.edu/acprod/odb_etd/ws/send_file/send?accession=osu1396967860&disposition=inline)

Ask based on this news for deep analysis...
Alpha Deep Research
Auto Accept Plan

Insights are generated using AI models and historical data for informational purposes only. They do not constitute investment advice or recommendations. Past performance is not indicative of future results.